Cephalon posts losses as revenue up 19 per cent
December 21st, 2007 Posted by: Dr. Cox
Cephalon has reported an increase of revenue for 2005 of 19 per cent to $1.2 billion. The firm’s total sales hit $1.16 billion, a rise of 18 per cent on 2004 levels, with the biggest seller being the narcolepsy drug Provigil (modafinil) with sales of $512.8 million. However, despite these figures the company made a loss for the year of $175 million, compared with a loss of $74 million in 2004.
Cephalon chairman and chief executive Frank Baldino said: “Cephalon delivered strong top- and bottom-line growth in 2005. “We also completed a series of acquisitions and collaborations that created a fully integrated oncology business and expanded our business geographically.” He added: “We continued to make progress in our plan to launch five new drugs. Finally, we eliminated uncertainty and added significant upside for our business by settling our litigation over Provigil. As a result, we enter 2006 in a position of strength, poised to deliver our best performance ever.”
© Adfero Ltd
Disclaimer
AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.